The FDA greenlights Lilly's Zepbound™ (tirzepatide) - a potent, new choice for managing persistent weight issues, including obesity or overweight cases with health issues connected to weight.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.

At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.

On October 26th, 2023, KangaBio announced that the FDA has formally approved their clinical trial application for the independently developed KGX101, a fusion protein recombined with IL-12 Fc for intravenous injection. Clinical trials will be held simultaneously in Australia and the US.

Sensei Biotherapeutics, Inc. revealed initial results from its Phase 1/2 trial's sole therapy dose-increase part for SNS-101, a selectively active human antibody targeting the VISTA immune checkpoint.

REGENXBIO Inc. reveals positive additional results from ongoing Phase II ALTITUDE® study. The study pertains to ABBV-RGX-314, expected for treating diabetic retinopathy except center-involved diabetic macular edema, and is given through in-office suprachoroidal delivery.

Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.

Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.

Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.